Biomedicine & Pharmacotherapy,
Journal Year:
2021,
Volume and Issue:
137, P. 111377 - 111377
Published: Feb. 16, 2021
Neurodegenerative
diseases
(NDs)
represent
a
common
neurological
pathology
that
determines
progressive
deterioration
of
the
brain
or
nervous
system.
For
treating
NDs,
comprehensive
and
alternative
medicines
have
attracted
scientific
researchers'
attention
recently.
Edible
mushrooms
are
essential
for
preventing
several
age-based
neuronal
dysfunctions
such
as
Parkinson's
Alzheimer's
diseases.
Mushroom
Grifola
frondosa,
Lignosus
rhinocerotis,
Hericium
erinaceus,
may
improve
cognitive
functions.
It
has
also
been
reported
edible
(basidiocarps/mycelia
extracts
isolated
bioactive
compounds)
reduce
beta-amyloid-induced
neurotoxicity.
Medicinal
being
used
novel
natural
compounds
help
modulate
immune
responses
possess
anti-cancer,
anti-microbial,
anti-oxidant
properties.
Compounds
polyphenols,
terpenoids,
alkaloids,
sesquiterpenes,
polysaccharides,
metal
chelating
agents
validated
in
different
ND
treatments.
This
review
aims
to
assess
mushrooms'
role
their
biomolecules
utilization
kinds
NDs.
The
action
mechanisms,
presented
here,
including
reducing
oxidative
stress,
neuroinflammation,
modulation
acetylcholinesterase
activity,
protecting
neurons
stimulation,
regulating
neurotrophins
synthesis.
We
provide
background
about
neurodegenerative
in-silico
techniques
drug
research.
High
costs
associated
with
experiments
current
ethical
law
imply
efficient
alternatives
limited
cost
value.
In
silico
approaches
an
method
low
successfully
implemented
cure
disorders
recent
days.
describe
applications
computational
procedures
molecular
docking,
virtual
high-throughput
screening,
dynamic
(MD)
simulation,
quantum-mechanical
methods
design.
They
were
against
various
targets
Cell & Bioscience,
Journal Year:
2020,
Volume and Issue:
10(1)
Published: April 1, 2020
Abstract
The
PI3
K/AKT/mTOR
signalling
pathway
plays
an
important
role
in
the
regulation
of
signal
transduction
and
biological
processes
such
as
cell
proliferation,
apoptosis,
metabolism
angiogenesis.
Compared
with
those
other
pathways,
components
PI3K/AKT/mTOR
are
complicated.
regulatory
mechanisms
functions
many
human
diseases,
including
ischaemic
brain
injury,
neurodegenerative
tumours.
inhibitors
include
single-component
dual
inhibitors.
Numerous
PI3K
have
exhibited
good
results
preclinical
studies,
some
been
clinically
tested
haematologic
malignancies
solid
In
this
review,
we
briefly
summarize
research
on
discuss
structural
composition,
activation,
communication
processes,
pathogenesis
diseases
Cells,
Journal Year:
2021,
Volume and Issue:
10(10), P. 2509 - 2509
Published: Sept. 22, 2021
The
RAF/MEK/ERK
signaling
pathway
regulates
diverse
cellular
processes
as
exemplified
by
cell
proliferation,
differentiation,
motility,
and
survival.
Activation
of
ERK1/2
generally
promotes
its
deregulated
activity
is
a
hallmark
many
cancers.
Therefore,
components
regulators
the
ERK
are
considered
potential
therapeutic
targets
for
cancer,
inhibitors
this
pathway,
including
some
MEK
BRAF
inhibitors,
already
being
used
in
clinic.
Notably,
kinases
also
have
pro-apoptotic
functions
under
certain
conditions
enhanced
can
cause
tumor
death.
Although
repertoire
compounds
which
mediate
activation
apoptosis
expanding,
various
anti-cancer
induce
while
exerting
their
anti-proliferative
effects,
mechanisms
underlying
ERK1/2-mediated
death
still
vague.
Recent
studies
highlight
importance
dual-specificity
phosphatases
(DUSPs)
determining
pro-
versus
anti-apoptotic
function
cancer.
In
review,
we
will
summarize
recent
major
findings
understanding
role
apoptosis,
focusing
on
mediating
ERK-dependent
apoptosis.
Studies
that
further
define
molecular
these
relevant
to
be
essential
harnessing
developing
effective
cancer
treatments.
Cells,
Journal Year:
2023,
Volume and Issue:
12(7), P. 1012 - 1012
Published: March 25, 2023
Parkinson’s
Disease
(PD)
is
the
second
most
common
neurodegenerative
disorder
seen,
especially
in
elderly.
Tremor,
shaking,
movement
problems,
and
difficulty
with
balance
coordination
are
among
hallmarks,
dopaminergic
neuronal
loss
substantia
nigra
pars
compacta
of
brain
aggregation
intracellular
protein
α-synuclein
pathological
characterizations.
Neuroinflammation
has
emerged
as
an
involving
mechanism
at
initiation
development
PD.
It
a
complex
network
interactions
comprising
immune
non-immune
cells
addition
to
mediators
response.
Microglia,
resident
macrophages
CNS,
take
on
leading
role
regulating
neuroinflammation
maintaining
homeostasis.
Under
normal
physiological
conditions,
they
exist
“homeostatic”
but
upon
stimuli,
switch
“reactive
state”.
Pro-inflammatory
(M1)
anti-inflammatory
(M2)
phenotypes
used
classify
microglial
activity
each
phenotype
having
its
own
markers
released
mediators.
When
M1
microglia
persistent,
will
contribute
various
inflammatory
diseases,
including
such
In
this
review,
we
focus
mediated
PD
also
signaling
pathways,
receptors,
involved
process,
presenting
studies
that
associate
microglia-mediated
inflammation
A
better
understanding
important
seeking
new
therapies
for
possibly
other
diseases.
Frontiers in Neuroscience,
Journal Year:
2022,
Volume and Issue:
16
Published: Sept. 1, 2022
Currently,
there
is
no
disease-modifying
treatment
available
for
Alzheimer's
and
Parkinson's
disease
(AD
PD)
that
includes
the
highly
controversial
approval
of
Aβ-targeting
antibody
aducanumab
AD.
Hence,
still
an
unmet
need
a
neuroprotective
drug
in
both
AD
PD.
Type
2
diabetes
risk
factor
Glucagon-like
peptide
1
(GLP-1)
hormone
growth
has
shown
effects
preclinical
studies,
success
GLP-1
mimetics
phase
II
clinical
trials
PD
raised
new
hope.
are
currently
on
market
as
treatments
type
diabetes.
analogs
safe,
well
tolerated,
resistant
to
desensitization
characterized
clinic.
Herein,
we
review
existing
evidence
illustrate
pathways
induced
following
GLP-1R
activation
neurons,
microglia
astrocytes.
The
latter
include
synaptic
protection,
improvements
cognition,
learning
motor
function,
amyloid
pathology-ameliorating
properties
(Aβ,
Tau,
α-synuclein),
suppression
Ca
Journal of Medicinal Chemistry,
Journal Year:
2022,
Volume and Issue:
65(24), P. 16033 - 16061
Published: Dec. 12, 2022
The
phosphoinositide
3-kinase
(PI3K)/protein
kinase
B
(AKT)/mammalian
target
of
rapamycin
(mTOR)
pathway
is
one
the
most
important
intracellular
pathways
involved
in
cell
proliferation,
growth,
differentiation,
and
survival.
Therefore,
this
route
a
prospective
biological
for
treating
various
human
diseases,
such
as
tumors,
neurodegenerative
pulmonary
fibrosis,
diabetes.
An
increasing
number
clinical
studies
emphasize
necessity
developing
novel
molecules
targeting
PI3K/AKT/mTOR
pathway.
This
review
focuses
on
recent
advances
ATP-competitive
inhibitors,
allosteric
covalent
proteolysis-targeting
chimeras
against
pathway,
highlights
possible
solutions
overcoming
toxicities
acquired
drug
resistance
currently
available
drugs.
We
also
provide
recommendations
future
design
development
promising
drugs
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: May 3, 2023
Neuropsychiatric
disorders
are
multifactorial
with
diverse
aetiological
factors.
Identifying
treatment
targets
is
challenging
because
the
diseases
resulting
from
heterogeneous
biological,
genetic,
and
environmental
Nevertheless,
increasing
understanding
of
G
protein-coupled
receptor
(GPCR)
opens
a
new
possibility
in
drug
discovery.
Harnessing
our
knowledge
molecular
mechanisms
structural
information
GPCRs
will
be
advantageous
for
developing
effective
drugs.
This
review
provides
an
overview
role
various
neurodegenerative
psychiatric
diseases.
Besides,
we
highlight
emerging
opportunities
novel
GPCR
address
recent
progress
development.